Company intelligence / Profile preview

Kaerus Bioscience

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

Kaerus has successfully completed a Phase 1 trial of its lead candidate KER‑0193, demonstrating proof of mechanism and safety in healthy volunteers. The drug showed effects on relevant brain activity measurements using EEG and was well-tolerated. Preparations are underway for a Phase 2 proof-of-concept study in Fragile X syndrome patients.

Therapeutic areas: Neurology
Modalities: Small molecules (BK channel modulators)
Industry: Biotech

Drug pipeline

1 asset

BK channel modulator (Kaerus Biosciences)

Preclinical

Partnerships

Medicxi Ventures (lead investor/partner)

Beyond the preview

Go deeper on Kaerus Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaerus Bioscience.